Inj. eptinezumab-jjmr 1 mg
Products billed under this code include Vyepti.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Vyepti.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Vyepti | Lundbeck Pharmaceuticals LLC | 67386-0130-51 | 100 | $2,124.30 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $21.243 | +$0.142 | 1 MG | Inj. eptinezumab-jjmr 1 mg | v1, posted September 17, 2026 |
| 3Q26 | $21.101 | +$0.555 | 1 MG | Inj. eptinezumab-jjmr 1 mg | v1, posted September 15, 2026 |
| 2Q26 | $20.546 | +$0.044 | 1 MG | Inj. eptinezumab-jjmr 1 mg | v1, posted September 15, 2026 |
| 1Q26 | $20.502 | +$0.528 | 1 MG | Inj. eptinezumab-jjmr 1 mg | v1, posted September 15, 2026 |
| 4Q25 | $19.974 | +$0.127 | 1 MG | Inj. eptinezumab-jjmr 1 mg | v1, posted September 8, 2026 |
| 3Q25 | $19.847 | +$0.526 | 1 MG | Inj. eptinezumab-jjmr 1 mg | v1, posted March 10, 2026 |
| 2Q25 | $19.321 | −$0.002 | 1 MG | Inj. eptinezumab-jjmr 1 mg | v1, posted March 10, 2026 |
| 1Q25 | $19.323 | +$0.63 | 1 MG | Inj. eptinezumab-jjmr 1 mg | v1, posted December 19, 2025 |
| 4Q24 | $18.693 | +$0.037 | 1 MG | Inj. eptinezumab-jjmr 1 mg | v1, posted June 11, 2025 |
| 3Q24 | $18.656 | +$0.608 | 1 MG | Inj. eptinezumab-jjmr 1 mg | v1, posted June 11, 2025 |
| 2Q24 | $18.048 | −$0.011 | 1 MG | Inj. eptinezumab-jjmr 1 mg | v1, posted March 11, 2025 |
| 1Q24 | $18.059 | +$0.625 | 1 MG | Inj. eptinezumab-jjmr 1 mg | v1, posted December 19, 2024 |
| 4Q23 | $17.434 | −$0.009 | 1 MG | Inj. eptinezumab-jjmr 1 mg | v1, posted October 10, 2024 |
| 3Q23 | $17.443 | +$0.435 | 1 MG | Inj. eptinezumab-jjmr 1 mg | v1, posted June 5, 2024 |
| 2Q23 | $17.008 | +$0.12 | 1 MG | Inj. eptinezumab-jjmr 1 mg | v1, posted February 23, 2024 |
| 1Q23 | $16.888 | +$0.477 | 1 MG | Inj. eptinezumab-jjmr 1 mg | v1, posted December 6, 2023 |
| 4Q22 | $16.411 | −$0.01 | 1 MG | Inj. eptinezumab-jjmr 1 mg | v1, posted June 22, 2023 |
| 3Q22 | $16.421 | +$0.41 | 1 MG | Inj. eptinezumab-jjmr 1 mg | v1, posted June 9, 2023 |
| 2Q22 | $16.011 | +$0.005 | 1 MG | Inj. eptinezumab-jjmr 1 mg | v1, posted December 14, 2022 |
| 1Q22 | $16.006 | +$0.371 | 1 MG | Inj. eptinezumab-jjmr 1 mg | v1, posted June 8, 2022 |
| 4Q21 | $15.635 | +$0.032 | 1 MG | Inj. eptinezumab-jjmr 1 mg | v1, posted June 2, 2022 |
| 3Q21 | $15.603 | −$0.006 | 1 MG | Inj. eptinezumab-jjmr 1 mg | v1, posted June 2, 2022 |
| 2Q21 | $15.609 | +$0.007 | 1 MG | Inj. eptinezumab-jjmr 1 mg | v1, posted March 1, 2022 |
| 1Q21 | $15.602 | – | 1 MG | Inj. eptinezumab-jjmr 1 mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.